Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2024.Sep.24

News

OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

2024.Aug.22

News

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs

2024.Aug.07

News

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

Read More

2024.Sep.25

Announcement

Announcement on behalf of OBIGEN of the Board’s resolution to lift the non-competition restrictions for CEO

2024.Sep.24

Announcement

Announcement of reference date of cash capital increase and share subscription

2024.Aug.07

Announcement

OBI receives US FDA Orphan Drug Designation for OBI-992 TROP2 ADC for the treatment of gastric cancer

2023 Annual Report

Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2024 BIO Asia Investment Summit

Download PDFAnnual Report

Read More

2024 Annual Shareholders’ Meeting

  • 2024.Jun.17 at 09:00 AM
  • Masterlink Securities Education and Training Center

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact